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Abstract The stimulatory effects of several DNA-binding basic
proteins (histone and protamine) and HIV-1 Rev with arginine
(Arg)-rich clusters on the activity of casein kinase II (CK-II)
were investigated in vitro. It was found that recombinant Rev
(rRev) and the synthetic oligo-fragments corresponding to the
amino acid sequences of its Arg-rich cluster stimulate CK-II
activity in a dose-dependent manner. The activated CK-II
phosphorylates several cellular and viral proteins in HIV-1
infected human MOLT-4 cells, and also phosphorylates HIV-1
structural proteins, including recombinant reverse transcriptase
(rRT). These phosphorylations are selectively inhibited by CK-II
inhibitors, such as quercetin, oGA (a glycyrrhetinic acid
derivative) and NCS-chrom (an enediyne containing antibiotic).
The data presented here suggest that HIV-1 Rev acts as an
effective potent activator of CK-II, which may be a cellular
mediator promoting HIV-1 replication in virus-infected cells.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Recent reports have demonstrated that casein kinase II
(CK-II), a second messenger-independent nuclear serine/
threonine protein kinase [1], plays an important role in pos-
itive and negative transcriptional regulation by speci¢c phos-
phorylation of several transcriptional factors (Sp1 [2], Ap1 [3],
serum response factor [4], upstream binding factor [5] and
steroid hormone receptor [6]). Recently, we reported that cer-
tain DNA-binding sperm proteins (protamines in ¢shes and
histones H2B2 and H2B3 in sea urchin) with oligo-Arg clus-
ters function as potent CK-II activators in vitro [7]. A com-
puter based protein sequence search for similar proteins con-
taining an Arg-rich cluster revealed: two DNA-binding
proteins (DNA terminal protein at positions 361^366 of hu-
man adenovirus type 5 [8] and nuclear antigen 3C at positions
74^80 of the Epstein-Barr virus [9]) ; and four retroviral gene
products (Rev at positions 35^50 and Tat at positions 49^57
of HIV-1 [10] ; Rev at positions 41^49 of simian immunode-
¢ciency virus (SIV) [11] ; and Rex (regulator in pX gene) at
positions 3^15 of human T-cell leukemia virus type 1 [12].
The stimulatory e¡ects of two recombinant HIV-1 proteins
(rRev and rTat) on CK-II activity was quantitatively deter-
mined using in vitro CK-II assay systems. Also, the inhibitory
e¡ects of some anti-viral substances on the CK-II-catalyzed
phosphorylation of viral proteins were examined. CK-II can
easily be partially puri¢ed from sea urchin eggs [7] and mouse
cells [13] as a hetero-complex with p99 (ERp99, a protein
from the Hsp-90 family) and p56 (calreticulin) using Mono
Q or glycyrrhizin-a⁄nity column chromatography (HPLC).
This hetero-complex provides convenient material for an in
vitro assay of CK-II activity, since CK-II in the complex
e¡ectively phosphorylates p99 and p56 by incubation with
ATP or GTP in the presence of a suitable CK-II activator
[13].
Our ¢ndings reveal a novel function of HIV-1 Rev as an
e¡ective potent activator of CK-II, which may therefore be a
cellular mediator responsible for promoting HIV-1 replication
in virus-infected cells. In addition, some anti-viral substances,
such as quercetin, oGA [13] and NCS-chrom [14], are charac-
terized here as potent inhibitors of CK-II, which is in agree-
ment with recent ¢ndings that other CK-II inhibitors (£avo-
noids and benzothiophenes) selectively inhibit HIV-1
transcription [15].
2. Materials and methods
2.1. Chemicals
[Q-32P]ATP (3000 Ci/mmol) was obtained from Amersham (Arling-
ton Heights, USA); poly-Arg, dephosphorylated K-casein (bovine
milk) and quercetin (3,3P,4P,5,7-pentahydroxy£avone) from Sigma
Chemical (St. Louis, USA); histones (calf thymus) from Boehringer-
Mannheim Biochemicals (Germany); and HIV-1 IIIB lysate (approx.
5.72U109 vp/ml (a sucrose density gradient puri¢ed virus: 1 mg pro-
tein/ml)) from ABI Advanced Bio-technologies Inc. (MD, USA). Rab-
bit polyclonal antibodies to recombinant HIV-1 proteins, such as RT,
gp41 and capsid proteins (p24 and p17), were obtained from Intracel
Co. (Cambridge, MD, USA). Neocarzinostatin (NCS, a macromolec-
ular antitumor antibiotic) was obtained from Kayaku Antibiotic Re-
search Laboratories Co., Ltd. (Tokyo). NCS-chrom was extracted
from NCS with 10% (v/v) methanol containing 0.1 N HCl, as reported
previously [14]. A glycyrrhetinic acid derivative (oGA [13]) was kindly
supplied by Minophagen Pharmaceutical Co., Ltd. (Tokyo).
2.2. Puri¢cation of rRev
Crude protein was extracted from E. coli transfected with pGEX-
2T/HIV-1 rev and grown overnight in soybean-casein digest (SCD)
FEBS 20303 29-5-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 5 3 8 - 9
*Corresponding author. Fax: (81) (427) 78 9406.
E-mail: ken@medcc.kitasato-u.ac.jp
Abbreviations: CK-II, casein kinase II; DTT, dithiothreitol; ERp99,
99-kDa endoplasmic reticulum protein; GST, glutathione-S-transfer-
ase; HIV-1, human immunodeficiency virus type 1; oGA, glycyr-
rhetinic acid derivative; NCS, neocarzinostatin; NCS-chrom, NCS-
chromophore; NLS, nuclear localization signal; PMSF, phenylmethyl-
sulfonyl fluoride; poly-Arg, poly-L-arginine; Rev, regulator of expres-
sion of virion proteins; rRev, recombinant Rev; rRT, recombinant
reverse transcriptase; SDS-PAGE, sodium dodecylsulfate polyacryl-
amide gel electrophoresis; Tat, transactivator of transcription
FEBS 20303 FEBS Letters 428 (1998) 235^240
medium containing ampicillin (100 Wg/ml) at 37‡C. The fusion protein
was induced with 0.1 WM IPTG (isopropyl-L-D-thiogalactopyranoside)
for 6 h. The bacterial pellet (about 15 g wet weight) was then soni-
cated for 60 s and mixed gently for 30 min in bu¡er (40 mM Tris-HCl
(pH 7.2), 2 mM DTT, protease inhibitors (0.1 WM PMSF, 0.5 WM
aminobenzamidine and 1 Wg/ml leupeptin) and 1% Triton X-100) con-
taining 1.0 M NaCl. After centrifugation (20 000Ug for 10 min at
4‡C), the supernatant (about 25 mg protein) was applied on a gluta-
thione-a⁄nity column after dialysis against bu¡er containing 0.1 M
NaCl. The partially puri¢ed GST-Rev fusion protein was cleaved
speci¢cally with thrombin. To obtain rRev, the reaction mixture
was directly applied onto a column of Superdex 200pg (HPLC). Elu-
tion was carried out with 20 mM phosphate bu¡er (pH 6.8) contain-
ing 0.5 M NaCl. The puri¢ed 13-kDa polypeptide was identi¢ed as a
Rev protein since the N-terminal partial amino acid sequence
(MAGRSGDSDE) corresponded to that of HIV-1 Rev.
2.3. Partial puri¢cation of CK-II from MOLT-4 cells
CK-II in a 1.5-M NaCl extract from human MOLT-4 cells (approx.
8U108 cells) was partially puri¢ed by means of phosphocellulose col-
umn chromatography. CK-II was eluted with 1.0 M NaCl after wash-
ing well with 0.4 M NaCl. Two e¡ective phosphate acceptors (p99 and
p56) for CK-II in the 1.0-M NaCl fraction were detected. CK-II and
its e¡ective phosphate acceptors in the phosphocellulose fraction were
further puri¢ed by means of gel ¢ltration on Superdex 200pg (HPLC),
as previously reported [13]. By determination of their N-terminal par-
tial amino acid sequences, p99 and p56 were identi¢ed as ERp99 (a
protein from the Hsp-90 family) and calreticulin (Ca2-binding pro-
tein), respectively, as reported previously [7,13].
2.4. Assay for CK-II activity
CK-II activity was measured in the standard reaction mixture (50
Wl), which comprised 40 mM Tris-HCl (pH 7.6), 2 mM DTT, 3 mM
Mn2, 20 WM [Q-32P]ATP (1000 cpm/pmol) and the indicated amount
of CK-II fraction containing native phosphate acceptors (p99 and
p56) prepared from MOLT-4 cells. After incubation for the indicated
periods at 30‡C in the presence or absence of the indicated CK-II
activators, the 32P-labeled p99 and p56 in the reaction mixtures
were detected by autoradiography after SDS-PAGE, as reported pre-
viously [7,13].
3. Results
3.1. Characterization of rRev as a potent activator of CK-II in
vitro
The biochemical characteristics of protein phosphorylation
by CK-II in the fraction prepared from MOLT-4 cells exactly
corresponded to those characterized with CK-IIs from sea
urchin eggs [7] and mouse cells [13], because CK-II activity
(phosphorylation of p99 and p56) was greatly stimulated by
basic polypeptides, such as salmine A1, poly-Arg (about 100
Arg residues) and poly-Lys (about 100 Lys residues), but
completely inhibited by heparin (a CK-II inhibitor) (data
not shown).
Using puri¢ed GST (glutathione-S-transferase)-Rev fusion
protein (GST-Rev) and rRev obtained from GST-Rev after
cleavage with thrombin (Fig. 1A), it was found that CK-II
activity was signi¢cantly stimulated when co-incubated with
rRev (Fig. 1B, lane 5), but not with GST (lane 4). rRev was
phosphorylated by CK-II in vitro (Fig. 1B, lane 5), as has
been reported by others [16]. Under the same experimental
conditions, rTat required higher doses (over 3 Wg/ml) to in-
duce signi¢cant stimulation of CK-II activity, and its stimu-
latory e¡ect was about one-third of rRev-induced CK-II stim-
ulation (data not shown).
Three synthetic oligo-fragments that act as nuclear local-
ization signals (NLSs) were used to determine the stimulatory
kinetics of CK-II activity (see Fig. 2 legend). The Rev oligo-
fragment (RQARRNRRRRWRERQR) stimulated CK-II-
catalyzed phosphorylation of p99 up to about 7.2-fold at
1 Wg/ml, in a manner similar to that observed with rRev
(Fig. 2A). In contrast, rTat and p120 oligo-fragments (Arg-
rich cluster regions) required higher doses (over 5 Wg/ml) to
induce comparable CK-II activity (Fig. 2B). The marked stim-
ulation of CK-II activity induced by the HIV-1 Rev oligo-
fragment was also observed with SIV Rev oligo-fragment
(RRQRRRRWRRR) (data not shown). Slight stimulation
of CK-II activity was induced with a minimum hepta-frag-
ment related to the Rev sequence at positions 38^44
(RRNRRRR), but not with a hepta-fragment of HIV-1 Tat
at positions 51^57 (KRRQRRR) nor of the NLS domain at
positions 126^132 (PKKKRKV) of SV-40 large T antigen.
Slight stimulation of CK-II activity was also observed when
a Lys-residue of the Tat hepta-fragment was substituted with
an Arg-residue. The rRev-induced stimulation of CK-II activ-
ity was reproduced when p99 and p56 were substituted with
other CK-II phosphate acceptors, such as casein or phosvitin.
These results show that, in vitro, (i) rRev is a more e¡ective
activator of oligomeric CK-IIs (K2L2, KKPL2 or KP2L2) than
rTat; and (ii) the Arg-rich cluster (NLS and Rev response
element (RRE) binding domains) of HIV-1 Rev is responsible
for activation of oligomeric CK-IIs. However, Arg-rich basic
polypeptides, such as salmine A1 and poly-Arg, have been
shown to have no stimulatory e¡ect on the activity of
K-monomeric CK-II (CK-IIK) [17].
3.2. Phosphorylation of viral proteins by CK-II in HIV-1
infected cells and HIV-1 lysate
To detect the viral gene products speci¢cally phosphoryl-
ated by CK-II in HIV-1-infected cells, the CK-II fractions
(phosphocellulose fractions) were prepared from HIV-1-in-
fected and uninfected MOLT-4 cells. Total phosphorylation
of substrate proteins contained in the CK-II fraction from
HIV-1-infected cells was about 1.4 times higher than that
determined in the kinase fraction from uninfected control
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Fig. 1. Selective puri¢cation of a GST-rRev fusion protein extracted
from E. coli transfected with pGEX-2T/HIV-1 rev by glutathione-af-
¢nity column chromatography. A: After treatment (2 h at 30‡C) of
GST-rRev (approx. 3 mg) with thrombin (2 units/ml), rRev was fur-
ther puri¢ed by gel ¢ltration on a Superdex 200pg column (HPLC).
SDS-PAGE (Coomassie Brilliant Blue R-250 staining) detected
GST-rRev (lane 1) in the glutathione-a⁄nity fraction and the puri-
¢ed Superdex fractions S-I (GST, lane 2) and S-II (rRev, lane 3).
B: To test the stimulatory e¡ects of GST-rRev, GST and rRev on
CK-II activity, the CK-II fraction (Mono Q fraction, approx. 2 Wg)
prepared from normal MOLT-4 cells was incubated for 20 min at
30‡C with 20 WM [Q-32P]ATP (1000 cpm/pmol) and 3 mM Mn2 in
the absence (lane 1) or presence (approx. 1 Wg each) of CK-II acti-
vators, poly-Arg (about 100 residues, lane 2), GST-rRev (lane 3),
GST (lane 4), or rRev (lane 5). Note that GST (lane 4), cleaved
from GST-rRev fusion protein by thrombin, has no e¡ect by itself.
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cells, after incubation for 20 min at 30‡C with 20 WM
[Q-32P]ATP in the presence of rRev as a CK-II activator. As
shown in Fig. 3A, in the absence of CK-II activators (lanes 1
and 3), a 99-kDa cellular polypeptide (p99) was mainly de-
tected as a 32P-labeled polypeptide. In contrast, in the pres-
ence of CK-II activators, a number of cellular polypeptides
highly phosphorylated by CK-II were detected (Fig. 3A). In-
terestingly, in HIV-1-infected cells (Fig. 3A, lane 4), at least
six phosphorylated proteins, with molecular weights of ap-
prox. 120 (a), 51 (b), 41 (c), 33 (d), 28 (e), and 24 kDa (f),
corresponded closely to the molecular sizes of HIV-1 gene
products: gp120 (external envelope protein, 120 kDa), p51
(reverse transcriptase, 51 kDa), gp41 (transmembrane domain
of envelope protein, 41 kDa), p32 (integrase, 32 kDa), p27
(Nef, 27 kDa) and p24 (capsid protein, 24 kDa), respectively.
To further con¢rm phosphorylation of HIV-1 structural
proteins by CK-II in vitro, HIV-1 lysate was directly incu-
bated for 20 min at 30‡C with puri¢ed CK-II and 20 WM
[Q-32P]ATP in the presence of rRev as a CK-II activator.
Fig. 3B (lane 3) shows that several polypeptides with molec-
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Fig. 3. Detection of polypeptides phosphorylated by CK-II in HIV-1-infected and uninfected MOLT-4 cells in vitro. A: The CK-II fractions
were separately prepared from the 1.5-M NaCl extracts of HIV-1-infected and uninfected cells (control) by one-step puri¢cation (phosphocellu-
lose column chromatography). The partially puri¢ed CK-II fractions (approx. 10 Wg) from HIV-1-infected and uninfected MOLT-4 cells were
separately incubated for 20 min at 30‡C wiht 20 WM [Q-32P]ATP (1000 cpm/pmol) and 3 mM Mn2 in the absence (lanes 1 and 3) or presence
(lanes 2 and 4) of rRev (approx. 5 Wg). The 32P-labeled polypeptides were then detected by autoradiography after SDS-PAGE: uninfected cells,
lanes 1 and 2; HIV-1-infected cells, lanes 3 and 4. B: Detection of 32P-labeled polypeptides after incubation of HIV-1 lysate with puri¢ed CK-
II in the presence of rRev as a CK-II activator or three CK-II inhibitors in vitro. HIV-1 IIIB lysate (approx. 5 Wg) was incubated for 20 min
at 30‡C with approx. 30 ng puri¢ed CK-II fraction (Mono Q fraction [13]), 20 WM [Q-32P]ATP (1000 cpm), 3 mM Mn2 and rRev (approx.
5 Wg). Lane 1, HIV-1 lysate alone; lane 2, HIV-1 lysate incubated with puri¢ed CK-II; lane 3, lane 2+rRev; lane 4, lane 3+10 WM oGA; lane
5, lane 3+2 WM quercetin; and lane 6, lane 3+0.15 WM NCS-chrom. C: Identi¢cation of RT (p66 and p51) in HIV-1 lysate by Western blotting
after SDS-PAGE. Lane 1, the structural proteins on the gel were detected by staining with amide black after SDS-PAGE; and lane 2, detection
of two polypeptides (p66 and p51) on the gel by Western blotting using rabbit polyclonal antibody to recombinant HIV-1 RT.
Fig. 2. The stimulatory e¡ects of rRev and three synthetic Arg-rich oligo-fragments corresponding to the amino acid sequences of Rev, Tat
and p120 on CK-II activity in vitro. The partially puri¢ed CK-II fraction (Mono Q fraction, approx. 5 Wg) was incubated for 20 min at 30‡C
with 20 WM [Q-32P]ATP (1000 cpm/pmol) in the presence or absence of the indicated basic oligo-fragments. The 32P-labeled p99 and p56 in the
reaction mixtures were detected by autoradiography after SDS-PAGE. CK-II fraction alone (lane 1 in A) or with rRev (1 Wg, lane 2 in A; b in
B); rRev (5 Wg, lane 3 in A; F in B) or rRev oligo-fragment (lanes 4 through 9, a^a) at doses of 0.1 Wg (lane 4), 0.3 Wg (lane 5), 1 Wg (lane 6),
3 Wg (lane 7), 10 Wg (lane 8), or 30 Wg (lane 9). The stimulatory e¡ects of synthetic oligo-fragments related to Tat (O^O) and p120 (E^E) on
CK-II activity were determined under the same experimental conditions. The Arg-rich oligo-fragments were: positions 35^50
(RQARRNRRRRWRERQR) of HIV-1 Rev; 49^61 (RKKRRQRRRPPQG) of HIV-1 Tat; and 41^55 (KRLSSRARKRAAKRR) of human
cell nuclear 120-kDa protein (p120). In B, a stimulation rate of 1 represents the CK-II-mediated phosphorylation of p98 determined in the ab-
sence of the CK-II activators.
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ular weights of approx. 120, 99, 51, 41, 38, 33 and 17 kDa in
HIV-1 lysate are highly phosphorylated by CK-II, but at least
four polypeptides (66, 38, p27 and 24 kDa) are poorly phos-
phorylated. Under the same experimental conditions, similar
protein phosphorylation by CK-II in HIV-1 lysate was ob-
served when other CK-II activators were used, such as poly-
Arg and Rev Arg-rich oligo-fragments (data not shown). As
shown in Fig. 3B, the CK-II-catalyzed phosphorylation of the
viral proteins was completely inhibited by co-incubation with
potent CK-II inhibitors known to exhibit anti-viral e¡ects:
oGA [13,18] (10 WM, lane 4); quercetin [19] (2 WM; lane 5);
or NCS-chrom [14] (0.15 WM, lane 6). The comparative ex-
periments con¢rmed that a 99-kDa phosphorylated polypep-
tide (p99) detected in Fig. 3B (lane 3) is ERp99 copuri¢ed
with CK-II from mouse liver [13]. Western blotting identi¢ed
p66 and p51 in HIV-1 lysate as reverse transcriptase (Fig. 3C),
and three major bands (41-, 24- and 17-kDa polypeptides) on
the gel (Fig. 3C, lane 1) were also identi¢ed as gp41 and
capsid proteins (p24 and p17), respectively.
From these results, it is concluded that (i) at least six poly-
peptides (gp120, RT (p66 and p51), gp41, capsid proteins (p27
and p17)) positively identi¢ed in HIV-1 lysate are viral gene
products phosphorylated by CK-II; and (ii) three compounds
(oGA, quercetin and NCS-chrom) with anti-viral e¡ects selec-
tively inhibit the CK-II-catalyzed phosphorylation of the viral
proteins in vitro.
3.3. Biological signi¢cance of the CK-II-catalyzed
phosphorylation of rRT (p66) in vitro
A computer-based protein sequence search, using Genetyx-
Mac/CD, revealed that HIV-1 RT (p66: RT (p51)-RNase H
(p15), 560 amino acids) has at least nine phosphorylation sites
(S/T-X-X-E/D) for CK-II as well as four sites for Ca2-de-
pendent protein kinase (C-kinase) and three sites for tyrosine
kinase. Indeed, both p66 and p51 in HIV-1-infected cells (Fig.
3A) and HIV-1 lysate (Fig. 3B) were slightly phosphorylated
by CK-II. Although recombinant RNase H-free RT (p51) was
an e¡ective phosphate acceptor rather than that of recombi-
nant RT (rRT, p66), the RT activity of RNase H-free rRT
(p51) was much less than that determined with rRT. There-
fore, rRT was used as a substrate for CK-II in the following
analytical experiments. As expected, puri¢ed rRT functioned
as a phosphate acceptor for CK-II in vitro (Fig. 4A, lane 2
and Fig. 4B). In an assay system using puri¢ed CK-II and
rRT, however, phosphorylation of rRT by CK-II was signi¢-
cantly reduced when incubated with Arg-rich oligo-fragments
related to HIV-1 Rev (Fig. 4A, lane 3) or HIV-1 Tat (lane 4).
In addition, GTP (10 WM, lane 5) and four CK-II inhibitors
(heparin (0.1 Wg/ml, lane 6), oGA (10 WM, lane 7), quercetin
(2 WM, lane 8) and NCS-chrom (0.15 WM, lane 9)) e¡ectively
inhibited CK-II-catalyzed phosphorylation of rRT (Fig. 4A).
Phosphorylation of rRT (p66) by CK-II in the absence of the
CK-II activators reached a plateau at 60 min under the given
experimental conditions (Fig. 4B).
To determine the physiological signi¢cance of the CK-II-
catalyzed rRT phosphorylation, RT activity was measured
after its incubation with CK-II and cold ATP in the presence
or absence of the CK-II inhibitors (Fig. 4C). The RT activity
of rRT was about 2.3-fold stimulated after its full phospho-
rylation by CK-II and this stimulation was inhibited when the
phosphorylation step included co-incubation with 2 WM quer-
cetin or 0.15 WM NCS-chrom, which alone did not a¡ect rRT
activity (Fig. 4C). These results suggest that CK-II mediates
the stimulation of RT activity of rRT in vitro.
4. Discussion
The results presented here suggest that CK-II is a cellular
mediator for activation of cellular factors involved in HIV-1
transactivation and for stimulation of the physiological activ-
ities of viral proteins in virus-infected cells. This possibility is
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Fig. 4. Characterization of CK-II-mediated phosphorylation of rRT
(p66) in vitro. A: rRT was puri¢ed to an apparently homogeneous
polypeptide (approx. 66 kDa, p66) from the crude protein extract
from E. coli BL21 transfected with pET21a(+)/HIV-1 rRT by means
of DEAE-cellulose column chromatography, gel ¢ltration on a
Superdex 200pg column and Mono Q column chromatography
(HPLC), successively. To characterize the CK-II-mediated phos-
phorylation of rRT, the puri¢ed rRT was incubated for 20 min at
30‡C with CK-II and 20 WM [Q-32P]ATP (1000 cpm/pmol) in the
presence of CK-II activators or inhibitors. The 32P-labeled rRT
(p66) in the reaction mixtures was detected by autoradiography
after SDS-PAGE. Lane 1, rRT alone; lane 2, rRT+CK-II; lane 3,
lane 2+Rev Arg-rich oligo-fragment; lane 4, lane 2+Tat Arg-rich
oligo-fragment; and rRT incubated with CK-II in the presence of
CK-II inhibitors (GTP (20 WM, lane 5), heparin (0.2 Wg/ml, lane 6),
oGA (10 WM, lane 7), quercetin (2 WM, lane 8) or NCS-chrom (0.15
WM, lane 9)). B: Puri¢ed rRT (approx. 1.0 Wg) was incubated for
the indicated periods at 30‡C with puri¢ed CK-II (approx. 20 ng)
and 20 WM [Q-32P]ATP (2000 Ci/pmol). The autoradiogram spectro-
photometer values are means of three repetitions. 100% represents
maximum phosphorylation of rRT by CK-II under the given experi-
mental conditions. Insert: Incubation for 0 min (lane 1), 15 min
(lane 2), 30 min (lane 3), 60 min (lane 4), 90 min (lane 5), 120 min
(lane 6), and for 120 min without CK-II (lane 7, F). C: To phos-
phorylate rRT (approx. 1.0 Wg) by CK-II, the protein was incubated
for 60 min at 30‡C with puri¢ed CK-II (approx. 30 ng), cold 50
WM ATP and 10 mM Mg2 in the presence or absence of a CK-II
inhibitor (2 WM quercetin or 0.15 WM NCS-chrom) at pH 8.0. After
full phosphorylation of rRT, RT activity was determined by subse-
quent incubation for 20 min at 30‡C with 10 WM [K-32P]dGTP
(2000 cpm/pmol) under the RT assay conditions [20]. The RT activ-
ity of phosphorylated rRT (mean of ¢ve di¡erent experiments) was
statistically signi¢cant (P6 0.001 using Student’s t-test). The stimu-
lation rate 1 represents the incorporation of approx. 5.2 pmol/Wg/
min of [K-32P]dGTP into the synthesized DNA fraction under the
given experimental conditions.
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strongly supported by the following evidence: (i) rRev and its
related Arg-rich fragments can e¡ectively stimulate CK-II ac-
tivity without substrate speci¢city (Figs. 1^3); (ii) the acti-
vated CK-II phosphorylates several cellular and viral proteins
in HIV-1-infected cells (Fig. 3A) and several viral proteins in
HIV-1 lysate (Fig. 3B); and (iii) CK-II mediates stimulation
of rRT activity (Fig. 4). In addition, both CK-II [21] and
HIV-1 Rev [22] are abundant in the nucleoplasm.
The ¢nding that three anti-viral substances (oGA, quercetin
and NCS-chrom) inhibit CK-II activity in a dose-dependent
manner without substrate speci¢city (Fig. 3), is basically con-
sistent with the recent report by Critch¢eld et al. [15], who
demonstrated that potent HIV-1 inhibitors, such as chrysin (a
£avonoid), benzothiophene and 5,6-dichloro-1-L-D-ribofura-
nosyl-benzimidazole (DRB), inhibit CK-II-catalyzed phos-
phorylation of cellular proteins involved in HIV-1 transcrip-
tion. Therefore, it seems that the selective inhibition of CK-II-
catalyzed phosphorylation of cellular and viral proteins may
be the mechanism by which CK-II inhibitors inhibit HIV-1
transactivation at the cellular level. Moreover, NCS-chrom
will be potentially useful as an e¡ective inhibitor of CK-II
for basic studies on its physiological role in the biochemical
processing of HIV-1 replication in virus-infected cells, because
the enediyne containing antibiotic selectively inhibits the CK-
II-mediated stimulation of rRT activity in vitro at low doses
(less than 0.15 WM). NCS-chrom also e¡ectively induces the
base-catalyzed cleavage of single-stranded DNA (ssDNA)
with a bulge structure, such as transcription response element
(TAR) DNA transcribed from HIV-1 RNA, at T-residues
[23].
It is well known that the NLS domain (RQARRNRRRR-
WRERQR) of HIV-1 Rev is involved in speci¢c binding of
RRE and nuclear/nucleolar localization [22], and that its ac-
tivation domain can interact with one or more cellular factors
required for Rev-induced transactivation in HIV-1-infected
cells [24]. Recently, it has been reported that phosphorylation
of HIV-1 Rev by CK-II, but not by CK-I, is implicated in
down-regulation of Rev at the cellular level [16]. We also
detected phosphorylation of rRev by CK-II (Fig. 2B, lane
5), and have observed that the binding ability of rRev to
RRE is signi¢cantly reduced through its phosphorylation by
CK-II in vitro (unpublished observation). This suggests that
(i) formation of the HIV-1 Rev-RRE complex may be regu-
lated by CK-II; and (ii) the protein-protein interaction be-
tween Rev and its cellular mediators, such as human Rev-
interacting protein (hRIP) [25], involved in the activation of
viral transcription may also be regulated by CK-II in HIV-1-
infected cells.
In the in vitro system using puri¢ed functional factors (CK-
II, rRT and rRev or rTat), it was found that an Arg-rich
oligo-fragment (NLS domain) of HIV-1 Rev signi¢cantly re-
duced the CK-II-catalyzed phosphorylation of rRT (Fig. 4A,
lane 3). Indeed, p66 (HIV-1 RT) was not much phosphory-
lated when the CK-II fraction from HIV-1-infected cells was
incubated with 20 WM [Q-32P]ATP (1000 cpm/pmol) and 3 mM
Mn2, in the presence of rRev as a CK-II activator (Fig. 3A,
lane 4). Both p66 and p51 in HIV-1 lysate were also poorly
phosphorylated by CK-II after direct incubation of the lysate
with puri¢ed CK-II and 20 WM [Q-32P]ATP (1000 cpm/pmol)
in the presence of rRev (Fig. 3B, lane 3). These results suggest
that (i) HIV-1 Rev may be an e¡ective potent activator for the
CK-II-catalyzed phosphorylation of several cellular factors
and some HIV-1 gene products, such as gp120, gp41 and
capsid proteins (p27 and p17), which are synthesized from
the late structural mRNAs of HIV-1 [22]; and (ii) the CK-
II-mediated stimulation of HIV-1 RT (p66) activity may be
unrelated to the cellular level of Rev in HIV-1-infected cells.
However, for understanding clearly the biological role of
HIV-1 Rev in the CK-II-catalyzed phosphorylation of cellular
transcriptional factors and viral gene products during HIV-1
replication, further analytical studies will be required to dis-
cover: (i) the protein-protein interaction between CK-II, RT
and Rev or Tat in vitro; and (ii) the regulatory mechanisms
involved in the physiological activities of cellular transcrip-
tional factors (Sp-1, Ap-1 and NFUB), viral gene products
(gp120, gp41, capsid proteins (p27 and p17) and protease
(p11)) and Rev-interacting proteins (RIPs) through their spe-
ci¢c phosphorylation by the Rev-activated CK-II in HIV-1-
infected cells.
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